复星医药为控股子公司提供重大担保，累计担保额逾218亿元——投资者需关注资产负债率及担保风险

主要内容摘要

• 复星医药（600196.SH）近期公告，为多家控股子公司提供新一轮担保，涉及金额合计超7亿元人民币。
• 截至2026年4月10日，集团累计对外担保金额折合人民币约21.86亿元，占2025年末净资产的44.86%。
• 部分被担保方资产负债率超过70%，存在一定经营及偿债风险。
• 全部担保均在已获股东大会审批的额度内，无需额外董事会或股东会批准。
• 本次担保未出现逾期，无新增对外担保对象，风险相对可控。

详细担保安排及被担保方情况

复星医药此次为7家控股子公司提供担保，单项最高担保金额达3.85亿元（复星医药产业）。各被担保方及金额如下：

• 复星医药产业： 担保金额3.85亿元，实际担保余额超10亿元。为其向招商银行、北京银行申请10年期贷款提供连带责任保证担保。
• 复星健康： 担保金额3亿元，担保余额2.09亿元。为其向招商银行申请36个月授信额度提供最高额连带责任保证，并有多重股权质押等反担保措施。
• 徐州星晨医院： 担保金额999万元，余额1.44亿元。复星健康为其向昆山农商行申请贷款担保，江苏引万以股权质押为反担保。
• 天津健嘉： 担保金额1500万元，余额3873万元。健嘉康复为其提供担保，天津润泽以股权质押及公司固定资产抵押为反担保。
• 济南健源： 担保金额880万元，余额2044万元。健嘉医疗为其提供担保，济南泰舜以股权质押为反担保。
• 昆山健嘉： 担保金额550万元，余额2613万元。健嘉医疗为其提供担保，汇聚海康以股权质押为反担保。
• 山东二叶： 担保金额1000万元，余额1亿元。苏州二叶为其提供担保，为全资子公司，不涉及反担保。

所有担保均为公司与其控股子公司之间，或控股子公司之间的内部担保，未产生对外第三方担保。

被担保方财务状况（2025年数据，未经审计）

对投资者的影响和潜在股价影响因素

• 担保规模大，杠杆效应突出： 截至2026年4月10日，复星医药集团累计对外担保额度达21.86亿元，占净资产近45%。高比例担保意味着公司对控股子公司的财务风险敞口较大，若相关子公司经营出现问题，母公司可能需承担实际还款责任，对集团整体财务稳健性构成压力。
• 部分子公司亏损，资产负债率高： 包括徐州星晨医院、济南健源、昆山健嘉等多家被担保子公司2025年净利润为负，且资产负债率高于70%。若不能有效改善经营，存在潜在坏账及母公司资金链压力，投资者需密切关注其后续经营表现。
• 担保风险相对可控： 多数担保已设置反担保措施（如股权质押、固定资产抵押等）；部分担保对象为全资、控股子公司，内部风险可控性较高，无逾期担保发生。但投资者仍需关注未来担保对象的经营风险与偿债能力变化。
• 所有担保均在已获批额度内： 本次担保不需另行董事会、股东会审批，反映公司在资金调度和风险管理上具备一定灵活性。
• 未来担保空间有限： 目前总授权额度为35亿元，已使用约7.87亿元，剩余可用额度约27.18亿元。若后续担保持续增长，需警惕潜在的整体风险上升。

投资者需关注事项

1. 关注被担保子公司的经营改善与偿债能力，尤其是亏损和高负债率企业。
2. 密切留意复星医药集团整体资产负债率变化及其对未来融资能力的影响。
3. 若后续出现子公司违约或担保责任实际发生，或对复星医药股价产生压力。
4. 本次担保事项虽为集团内部安排，但规模较大，若市场解读为债务风险提升，可能影响股价波动。

结论

复星医药本次为控股子公司提供大额担保，显示出公司对旗下产业链的资金支持和持续扩张意愿。然而，部分被担保子公司当前盈利能力不足、资产负债率较高，整体担保规模占集团净资产比重已接近45%。尽管风险可控、暂无逾期，但随着担保额度持续增长，投资者需密切关注集团及子公司的经营动态和财务健康状况，以防潜在风险释放对公司估值及股价造成影响。

免责声明： 本文所载信息仅供参考，不构成任何投资建议。投资者据此操作，风险自负。请结合自身风险偏好审慎决策。

English Version

Fosun Pharma Provides Over RMB 2.18 Billion in Guarantees to Subsidiaries—Investors Should Note Leverage and Guarantee Risks

Key Points

• Fosun Pharma (600196.SH) announced new guarantees for several subsidiaries, with a total amount exceeding RMB 700 million.
• As of April 10, 2026, the group’s total external guarantee balance is about RMB 2.186 billion, accounting for 44.86% of the group’s audited net assets at the end of 2025.
• Some guaranteed subsidiaries have asset-liability ratios over 70%, indicating business and repayment risks.
• All guarantees fall within previously approved limits and do not require additional board or shareholder approval.
• No overdue guarantees or new third-party guarantees; the risk remains relatively controllable.

Details of Guarantee Arrangements and Subsidiary Conditions

Fosun Pharma is providing guarantees to seven subsidiaries, the largest being RMB 385 million (Fosun Pharma Industrial). The main entities and amounts are:

• Fosun Pharma Industrial: RMB 385 million guarantee, with a total guarantee balance over RMB 1 billion, for a 10-year syndicated loan from CMB and Bank of Beijing.
• Fosun Health: RMB 300 million guarantee, balance RMB 209 million, for a 36-month credit facility from CMB, with multiple counter-guarantees including equity pledges.
• Xuzhou Xingchen Hospital: RMB 9.99 million guarantee, balance RMB 144 million, with counter-guarantee from Jiangsu Yinwan via equity pledge.
• Tianjin Jianjia: RMB 15 million guarantee, balance RMB 38.7 million, counter-guaranteed by Tianjin Runze and company assets.
• Jinan Jianyuan: RMB 8.8 million guarantee, balance RMB 20.44 million, counter-guaranteed by Jinan Taishun via equity pledge.
• Kunshan Jianjia: RMB 5.5 million guarantee, balance RMB 26.13 million, counter-guaranteed by Huiju Haikang via equity pledge.
• Shandong Erye: RMB 10 million guarantee, balance RMB 100 million, fully-owned by Suzhou Erye, no counter-guarantee required.

All guarantees are internal to the group (between the company and its subsidiaries), with no new external third-party guarantees.

Financial Status of Subsidiaries (2025, Unaudited)

Investor Impact and Potential Price-Sensitive Factors

• Large Guarantee Scale and High Leverage: Aggregate guarantees represent nearly 45% of the group’s net assets, increasing the group’s financial risk exposure. Any deterioration in subsidiary operations could lead to parent company cash outflows, affecting financial health and valuation.
• Loss-Making, Highly Leveraged Subsidiaries: Several subsidiaries are loss-making with high debt ratios. Continued poor performance may result in potential bad debts or call on guarantees, impacting group liquidity and share price.
• Counter-Guarantees Mitigate Risk: Most guarantees have counter-guarantees (equity/fixed asset pledges). All guarantees are internal, and there are currently no overdue cases.
• All Guarantees Within Approved Limits: The company retains flexibility and does not need to seek additional shareholder or board approval for these guarantees.
• Limited Future Guarantee Headroom: Of the total RMB 35 billion approved, about RMB 7.87 billion is used, leaving RMB 27.18 billion available. Expansion of guarantees in the future may increase risk profile.

Key Points for Investors

1. Monitor financial performance and repayment ability of loss-making and highly leveraged subsidiaries.
2. Pay attention to the group’s overall leverage and financing capacity.
3. Any future default or actual guarantee execution could pressure the group’s stock price.
4. While these are internal arrangements, the large scale may be interpreted by the market as increased debt risk, impacting share price volatility.

Conclusion

Fosun Pharma’s new round of large guarantees underscores its commitment to supporting its industrial chain and expansion. However, with some subsidiaries operating at a loss and with high leverage, and the guarantee amount approaching 45% of the group’s net assets, the overall risk is rising. Investors should closely monitor the financial health of both the group and its subsidiaries to avoid potential adverse impacts on company valuation and share price.

Disclaimer: The above content is for informational purposes only and does not constitute investment advice. Investors are responsible for their own decisions and assume all risks.

View 复星医药 Historical chart here